Wockhardt (WOCKPHARMA) Share Price Falls 2.42% Today as Stock Slips to Rs 1,837.90

Wockhardt Share Price fell to Rs 1,837.90 on 01 September 2026, down 2.42% for the day, taking the decline to Rs 45.65 from the previous close of Rs 1,883.55. The company’s market capitalisation stood at Rs 32,103.58 crore, placing it in the Large Cap category.

Today’s move is drawing attention because the verified data confirms a same-day decline, but it does not establish any company-specific catalyst behind it. The stock opened at Rs 1,883.55, touched an intraday high of Rs 1,910, and then slipped to a low of Rs 1,834.50 before hovering near that lower end of the day’s range. Turnover stood at Rs 4.65 crore.

For investors tracking Wockhardt, the near-term focus is on three areas: whether the stock stabilises after trading below its 50-day moving average of Rs 1,915.73, how its valuation compares with the Pharmaceuticals & Drugs industry benchmark, and whether current profitability ratios support the prevailing multiple. Univest reviews the price move, sector context and peer positioning below.

Wockhardt (WOCKPHARMA) Share Price Today: Price Action Analysis

Metric	Value
Current Price	Rs 1,837.9
Previous Close	Rs 1,883.55
Today's Move	-Rs 45.65 (-2.42%)
Open	Rs 1,883.55
High	Rs 1,910
Low	Rs 1,834.5
Turnover	Rs 4.65 crore
Market Capitalisation	Rs 32,103.58 crore
Market Cap Category	Large Cap

Wockhardt Share Price Today reflects a clear intraday loss, with the stock moving from Rs 1,883.55 to Rs 1,837.90, a decline of Rs 45.65 or 2.42%. The move matters because the session began flat at the previous close, briefly extended to Rs 1,910, and then reversed enough to test Rs 1,834.50.

The spread between the day’s high and low shows active trading through the session. Trading near the intraday low rather than rebounding toward the open suggests selling pressure persisted later in the day. Turnover of Rs 4.65 crore also shows that the counter remained in focus, especially given its Large Cap classification and market cap of Rs 32,103.58 crore.

For readers following the stock closely, the available data confirms the decline itself but does not identify a specific trigger. That makes the next layer of analysis more relevant: valuation, profitability, and relative standing within the pharma pack.

Wockhardt (WOCKPHARMA) Fundamental Analysis

Metric	Value
Market Capitalisation	Rs 32,103.58 crore
P/E Ratio	74.83x
P/B Ratio	6.08x
ROE	4.29%
ROCE	6.79%
EPS	Rs 25.17
Book Value Per Share	Rs 309.81
Dividend Yield	0%

Wockhardt’s current fundamental snapshot shows a relatively elevated valuation alongside moderate profitability. At the available price, the company trades at a P/E ratio of 74.83 and a P/B ratio of 6.08. EPS stands at 25.17, while book value per share is Rs 309.81.

Return ratios are comparatively subdued in the supplied data. ROE is 4.29% and ROCE is 6.79%, indicating positive but not especially strong returns on equity and capital employed. Dividend yield is 0, so the present case in the available numbers is linked more to valuation and earnings expectations than to cash payout.

Market capitalisation at Rs 32,103.58 crore is substantial, but size alone does not settle the valuation question. With a P/E of 74.83 against ROE of 4.29% and ROCE of 6.79%, the stock naturally invites comparison with the broader Pharmaceuticals & Drugs benchmark and with large listed peers.

Sector and Industry Context

Metric	Value
Sector	Healthcare
Industry	Pharmaceuticals & Drugs
Benchmark Scope	same industry
Company P/E Ratio	74.83x
Benchmark Median P/E	30.92x
Benchmark Average P/E	48.02x
Benchmark P/E Range	3.87x to 667.16x
Company P/B Ratio	6.08x
Benchmark Median P/B	2.88x
Benchmark Average P/B	4.34x
Company ROE	4.29%
Benchmark Median ROE	11.81%
Benchmark Average ROE	11.21%
Company ROCE	6.79%
Benchmark Median ROCE	13.65%
Benchmark Average ROCE	13.76%
Company Market Capitalisation	Rs 32,103.58 crore
Benchmark Median Market Cap	Rs 683.05 crore
Benchmark Average Market Cap	Rs 14,252.9 crore

Wockhardt operates in the Healthcare sector and the Pharmaceuticals & Drugs industry. The benchmark snapshot gives useful context for the current decline because it shows valuation above central industry levels, while profitability trails benchmark medians and averages.

The industry benchmark covers 201 companies. Within that universe, Wockhardt’s P/E of 74.83 is above the industry median of 30.92 and above the average of 48.02, though still far below the maximum of 667.16. The P/E sample count is 168, with a minimum of 3.87. On price-to-book, Wockhardt’s 6.08 is above the median of 2.88 and average of 4.34 across 199 companies, within a range of -11.1 to 27.39.

Profitability looks softer versus the same industry. ROE of 4.29% trails the industry median of 11.81% and average of 11.21%, while ROCE of 6.79% is below the median of 13.65% and average of 13.76%. At the same time, market capitalisation of Rs 32,103.58 crore is above the industry median of Rs 683.05 crore and the average of Rs 14,252.90 crore. That mix of large size, premium valuation and weaker return ratios remains central to how the stock is being assessed.

Peer Comparison

Company	Symbol	Market Cap (Cr)	P/E	P/B	ROE (%)	ROCE (%)
Sun Pharmaceutical Industries	SUNPHARMA	4,60,696.31	38.8	5.43	14.85	19.11
Divi's Laboratories	DIVISLAB	2,46,062.83	83.91	13.89	16.19	21.51
Torrent Pharmaceuticals	TORNTPHARM	1,91,515.22	86.82	21.1	26.76	19.27
Zydus Lifesciences	ZYDUSLIFE	1,18,403.7	25.69	4.3	19.69	21.39
Cipla	CIPLA	1,14,554.33	33.94	3.25	11.83	16

Against major listed pharmaceutical peers, Wockhardt occupies a middle ground on valuation but lags more clearly on profitability. Its P/E of 74.83 is higher than Sun Pharmaceutical Industries at 38.8, Zydus Lifesciences at 25.69 and Cipla at 33.94, but lower than Divi's Laboratories at 83.91 and Torrent Pharmaceuticals at 86.82.

On P/B, Wockhardt’s 6.08 sits above Sun Pharma’s 5.43, Zydus’ 4.3 and Cipla’s 3.25, but below Divi’s 13.89 and Torrent’s 21.1. The sharper contrast is on returns: ROE of 4.29% is below Sun Pharma’s 14.85%, Divi’s 16.19%, Torrent’s 26.76%, Zydus’ 19.69% and Cipla’s 11.83%. ROCE shows the same pattern, with Wockhardt at 6.79% against 19.11%, 21.51%, 19.27%, 21.39% and 16.0% respectively.

Size-wise, its market cap of Rs 32,103.58 crore is well below Sun Pharma at Rs 4,60,696.31 crore, Divi’s at Rs 2,46,062.83 crore, Torrent at Rs 1,91,515.22 crore, Zydus at Rs 1,18,403.70 crore and Cipla at Rs 1,14,554.33 crore. So the stock is being judged in a peer frame where valuation is not low, while return ratios remain weaker than several established competitors.

Why Investors Are Watching Wockhardt

• Wockhardt Share Price fell 2.42% today to Rs 1,837.90 after touching a high of Rs 1,910 and a low of Rs 1,834.50.
• The stock is trading below its 50-day moving average of Rs 1,915.73, while remaining above its 200-day moving average of Rs 1,621.31.
• Its valuation remains elevated at 74.83 times earnings and 6.08 times book value.
• Profitability metrics are modest, with ROE at 4.29% and ROCE at 6.79%.
• Within Pharmaceuticals & Drugs, its P/E is above industry median and average levels, keeping sector comparison in focus.

About Wockhardt

Wockhardt is part of the Healthcare sector and is classified under the Pharmaceuticals & Drugs industry. In market terms, it is a Large Cap pharmaceutical company with a market capitalisation of Rs 32,103.58 crore. That places it in a segment where investors often compare valuation multiples, profitability ratios and stock performance directly against large listed drug makers.

Because the supplied company data is sector-led rather than business-description led, the clearest verified context is its position within India’s listed pharmaceuticals space. For readers following the company, the stock is currently being judged through the lens of price action, return ratios and relative valuation within healthcare.

Track Wockhardt Share Price on Univest

Use Wockhardt (WOCKPHARMA) live share-price page,Univest top decliners screener,Univest market blogsto review live stock data, top decliners and related market analysis.

On Univest, investors can track Wockhardt Share Price, market capitalisation, valuation ratios, moving averages, RSI, and broader market insights in one place. The platform also helps users compare stock performance with sector peers and follow ongoing company-related market updates without relying on scattered sources.

Frequently Asked Questions

Why is Wockhardt Share Price falling today?

Ans.  Wockhardt Share Price is down because the stock declined Rs 45.65, or 2.42%, to Rs 1,837.90 from the previous close of Rs 1,883.55. The supplied data confirms the fall, but it does not establish a company-specific catalyst.

What is Wockhardt Share Price Today?

Ans.  Wockhardt Share Price Today is Rs 1,837.90. The stock opened at Rs 1,883.55, touched an intraday high of Rs 1,910, and slipped to a low of Rs 1,834.50. The previous close was Rs 1,883.55.

How much did Wockhardt stock fall today?

Ans.  Wockhardt stock fell by Rs 45.65 in today’s session, which translates into a 2.42% decline from the previous close of Rs 1,883.55. The move brought the stock down to Rs 1,837.90.

Is Wockhardt a large-cap stock?

Ans.  Yes, Wockhardt is classified as a Large Cap stock in the supplied market data. Its market capitalisation stands at Rs 32,103.58 crore, making it much larger than the industry median market cap of Rs 683.05 crore.

What does Wockhardt’s valuation look like?

Ans.  Wockhardt trades at a P/E ratio of 74.83 and a P/B ratio of 6.08. Both are above the Pharmaceuticals & Drugs industry median levels of 30.92 and 2.88, indicating a relatively richer valuation versus the benchmark centre.

How profitable is Wockhardt based on current ratios?

Ans.  Wockhardt’s ROE is 4.29% and ROCE is 6.79%. These profitability ratios are below the industry medians of 11.81% and 13.65%, suggesting current returns are modest relative to the broader Pharmaceuticals & Drugs benchmark.

How does Wockhardt compare with major pharma peers?

Ans.  Wockhardt’s P/E of 74.83 is above Sun Pharma, Zydus and Cipla, but below Divi’s and Torrent. Its ROE of 4.29% and ROCE of 6.79% are lower than all five highlighted peers in the supplied comparison.

What should investors monitor next in Wockhardt?

Ans.  Investors may track whether Wockhardt sustains above its 200-day moving average of Rs 1,621.31 and whether it can regain the 50-day moving average of Rs 1,915.73. Valuation versus peer profitability also remains an important watchpoint.

Where can I track Wockhardt Share Price and stock analysis?

Ans.  You can track Wockhardt Share Price on Univest for live price updates, valuation ratios, moving averages, RSI readings, sector comparisons and broader stock analysis. That helps place daily moves like today’s 2.42% decline in a wider context.